A clinical case of the effectiveness of chemo-targeted therapy in the first line of treatment for recurrent squamous cell carcinoma of the larynx

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer, with laryngeal cancer accounting for only 0.6%. According to GLOBOCAN estimates (2022), approximately 890,000 new cases of HNSCC are registered worldwide each year, with mortality estimated at 450,000. In Russia in 2023, laryngeal cancer accounted for 2% of all malignant neoplasms among the male population. Despite the treatment, more than 50% of patients experience a relapse of the disease in the first 3 years. Modern methods of treating metastatic or recurrent HNSCC include both standard cytostatics and modern classes of antitumor drugs (targeted and immunotherapy).

Description of a clinical case: This article presents a clinical case of a long-term response to combined chemo-targeted (paclitaxel, carboplatin, cetuximab) therapy in a patient with recurrent squamous cell carcinoma of the larynx.

Conclusion: Combination chemo-targeted therapy (paclitaxel, carboplatin, cetuximab) as first-line treatment for recurrent/metastatic HNSCC demonstrates satisfactory tolerability with comparable oncological outcomes, especially in older patients and/or with significant comorbidities.

Full Text

Restricted Access

About the authors

Ekaterina A. Novgorodova

N.I. Pirogov Russian National Research Medical University

Email: golubev194@gmail.com
ORCID iD: 0009-0004-3111-7663

Student, Faculty of General Medicine

Russian Federation, Moscow

Pavel V. Golubev

A. Tsyb Medical Radiology Research Center – Branch of the National Medical Research Radiological Center

Email: golubev194@gmail.com
ORCID iD: 0000-0003-3532-6476

Cand. Sci. (Med.), Oncologist, Department of Antitumor Drug Therapy

Russian Federation, Obninsk

Evgenia S. Kuzmina

Moscow City Hospital named after S.S. Yudin

Email: golubev194@gmail.com
ORCID iD: 0009-0007-2856-5176

Cand. Sci. (Med.), Head of Chemotherapy Department No. 2, Oncology Center No. 1

Russian Federation, Moscow

Dmitry S. Pikulin

Moscow City Hospital named after S.S. Yudin

Email: golubev194@gmail.com
ORCID iD: 0009-0000-1037-9729

Oncologist, Day Hospital for Antitumor Drug Therapy No. 2, Oncology Center No. 1

Russian Federation, Moscow

Vladislav M. Kuzmin

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: golubev194@gmail.com
ORCID iD: 0009-0000-9658-3586

Student

Russian Federation, Moscow

Vsevolod N. Galkin

Moscow City Hospital named after S.S. Yudin

Author for correspondence.
Email: golubev194@gmail.com
ORCID iD: 0000-0002-6619-6179

Dr. Sci. (Med.), Professor, Chief Physician

Russian Federation, Moscow

References

  1. Barsouk A., Aluru J.S., Rawla P., et al. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023;11(2):42. https://dx.doi.org/10.3390/medsci11020042
  2. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна и др. М., 2024. илл. 276 с. [Malignant neoplasms in Russia in 2023 (morbidity and mortality). Ed. by A.D. Kaprin et al. Moscow, 2024. ill. 276 p. (In Russ.)].
  3. PDQ Adult Treatment Editorial Board. Laryngeal Cancer Treatment (PDQ®): Health Professional Version. 2025 Feb 25. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US). 2002.
  4. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27. doi: 10.1056/NEJMoa0802656
  5. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В. и др. Опухоли головы и шеи. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2024;14(3s2):160–82. [Bolotina L.V., Vladimirova L.Yu., Dengina N.V., et al. Tumors of the head and neck. RUSSCO practical recommendations, part 1.1. Malignant neoplasms 2024;14(3s2):160–82. (In Russ.)].
  6. Rodrigo J.P., López-Álvarez F., Medina J.E., et al. Treatment of the neck in residual/recurrent disease after chemoradiotherapy for advanced primary laryngeal cancer. Eur J Surg Oncol. 2024;50(7):108389. https://dx.doi.org/10.1016/j.ejso.2024.108389
  7. Machiels J.-P., et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462–75.
  8. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27. https://dx.doi.org/10.1056/NEJMoa0802656
  9. Guigay J., Fayette J., Dillies A.F., Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol. 2015;26(9):1941–7. https://dx.doi.org/10.1093/annonc/mdv268
  10. Guigay J., et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial Guigay, JoëlBABA-HAMED, NabilATZPODIEN, JensADANSA KLEIN, Lancet Oncol. 2021;22(4):463–75.
  11. Guigay J., Aupérin A., Fayette J., et al.; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463–75. https://dx.doi.org/10.1016/S1470-2045(20)30755-5
  12. Carinato H., Burgy M., Ferry R., et al. Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients. Front Oncol. 2021;11:714551. https://dx.doi.org/10.3389/fonc.2021.714551
  13. Tahara M., et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) Ann Oncol. 2018;29(4):1004–9.
  14. Forman R., et al. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. JC 2021;39:60422. https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.6042
  15. Geraghty L., Schultz T.E., Hoffman S.E., et al. Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer. Mol Clin Oncol. 2021;15(5):240. https://dx.doi.org/10.3892/mco.2021.2403
  16. Vermorken J.B., et al. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy. JCO. 2007;25:2171–7. https://dx.doi.org/10.1200/ JCO.2006.06.7447

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure 1. Patient's appearance оп the background of СТ (paclitaxel + carboplatin + cetuximab)

Download (257KB)
Indexing metadata
3. Figure 2. Patient's арреаrаnсе on the background of СТ (paclitaxel + carboplatin + cetuximab)

Download (214KB)
Indexing metadata
4. Figure 3. Overall (А) and relapse-free (В) survival in the study by М. Tahara et al.

Download (99KB)
Indexing metadata
5. Figure 4. Relapse-free (А) and overall (В) survival in the study by L. Geraghty et al.

Download (142KB)
Indexing metadata

Copyright (c) 2025 Bionika Media